Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease.

[1]  C. Putterman,et al.  Macrophage depletion ameliorates nephritis induced by pathogenic antibodies. , 2015, Journal of autoimmunity.

[2]  L. Schwartz,et al.  Human Skin Mast Cells Express Complement Factors C3 and C5 , 2013, The Journal of Immunology.

[3]  S. Barnum,et al.  Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE. , 2013, Molecular immunology.

[4]  John D. Lambris,et al.  Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms , 2013, The Journal of Immunology.

[5]  H. Anders,et al.  Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  V. M. Holers,et al.  Role of C3a Receptors, C5a Receptors, and Complement Protein C6 Deficiency in Collagen Antibody-Induced Arthritis in Mice , 2012, The Journal of Immunology.

[7]  H. Sekine,et al.  The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. , 2011, Arthritis and rheumatism.

[8]  G. Tsokos,et al.  Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice. , 2010, Arthritis and rheumatism.

[9]  J. Thurman,et al.  The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. , 2007, American journal of physiology. Renal physiology.

[10]  M. van Lookeren Campagne,et al.  A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis , 2007, The Journal of experimental medicine.

[11]  P. Vezina,et al.  Absence of functional alternative complement pathway alleviates lupus cerebritis , 2007, European journal of immunology.

[12]  G. Gilkeson,et al.  Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. , 2007, The American journal of pathology.

[13]  L. Diehl,et al.  CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens , 2006, Cell.

[14]  J. Atkinson.  Complement activation and complement receptors in systemic lupus erythematosus , 2005, Springer Seminars in Immunopathology.

[15]  V. Kelley,et al.  IL-12 Deficiency in MRL-Faslpr Mice Delays Nephritis and Intrarenal IFN-γ Expression, and Diminishes Systemic Pathology1 , 2003, The Journal of Immunology.

[16]  R. Quigg,et al.  Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. , 2003, Journal of the American Society of Nephrology : JASN.

[17]  Q. Hu,et al.  Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. , 1996, Proceedings of the National Academy of Sciences of the United States of America.